Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, T-Cell, Cutaneous

Lymphoma, T-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

Cutaneous T-cell Lymphoma

* An additional punch from lesion skin as part of a skin biopsy performed as part of routine care.
* an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care.
* In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research.

Biologic Samples

Adèle DE MASSON

Matthieu RESCHE-RIGON

Cutaneous lymphomas are a heterogeneous group of extra-nodal lymphomas. The prognosis of cutaneous lymphomas is extremely variable from one subject to another. In the majority of cases, there is no cure for cutaneous lymphomas. Cutaneous lymphomas primarily affect the skin, and secondarily the blood, lymph nodes and possibly other organs. The discovery of new molecular prognostic factors will allow a better identification of patients at high risk of aggressive evolution and the implementation of a personalized therapeutic strategy. The identification of new therapeutic targets is necessary in order to develop new innovative treatments for cutaneous lymphomas.The primary objective is to identify novel molecular prognostic factors associated with 5-year overall survival in cutaneous lymphoma.

Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas

Assistance Publique - Hôpitaux de Paris

Digestive System Diseases

Gland and Hormone Related Diseases

Skin and Connective Tissue Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Pancreatic Neoplasms

Melanoma

Lung Neoplasms

Hematologic Neoplasms

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Hematologic Diseases

Pancreatic Cancer

Dermatologic Agents

All Drugs and Chemicals

Coal Tar

Participants \>= 18 with a suspected or confirmed solid tumor malignancy that requires surgery or biopsy.

Participants \>= 18 who have a known or suspected hematologic malignancy that requires surgery or biopsy.

Steven A Rosenberg, M.D.

Background:

Many advances have been made in cancer treatments, but more research is needed. Comparing samples of cancerous tissue to samples of normal, noncancerous tissues may help find differences between them. These differences may help researchers find new ways to treat cancer.

Objective:

To collect tissues and blood samples from people with known or suspected cancer. The samples will be used to help identify new targets for cancer treatments.

Eligibility:

People aged 18 years and older with a known or suspected cancer that requires surgery or biopsy.

Design:

Participants will be screened. They will answer questions about their health. They can do this on the phone or in person.

Researchers will collect information from participants medical records. Data may include information about any prior or current cancers. Data about other medical conditions may also be collected.

Participants will have blood drawn. Some of the blood will be tested for HIV and hepatitis B and C. Some of the blood will be used for genetic research.

Participants will have tissue samples collected during surgeries or biopsies. These are procedures the participants would have had as part of their standard care. No new procedures will be done just for this study. Researchers may also seek out samples from prior procedures the participant had done.

Participants will remain in the study for 6 months. They may have blood drawn again. Researchers may also collect tissue samples from any procedures performed during that time.

Background:

* Recent advances and insights into the molecular pathogenesis of cancer have led to the development of novel molecular and biologic targeted therapies for the treatment of advanced cancer participants. A critical challenge in extending these studies involves the identification and validation of new therapeutic targets for future cancer therapies.
* The development of immuno-oncology therapeutics across a wide spectrum of malignancies has emphasized a need to understand the intratumoral immunologic landscape of metastatic cancer. The techniques of cultivating and examining tumor infiltrating lymphocytes developed in the Surgery Branch can be expanded and refined by the exploration of solid tumors.
* The Surgery Branch, NCI has an interest in identifying novel molecular and biologic targets to facilitate the development of future cancer therapies for solid and hematologic malignancies. Through close collaborations with the Surgical Oncology Program and Thoracic Surgery Branch, our internal staff surgeons, and our medical oncology staff clinicians, we are uniquely positioned to acquire and perform important studies on solid tumor tissue and bone marrow to help identify therapeutic targets that may have significant clinical ramifications.

Objective:

To collect biologic samples from participants undergoing diagnostic or therapeutic interventions for known or suspected cancer for the purpose of identifying novel molecular and biologic therapeutic targets and studying the intratumoral immune landscape.

Eligibility:

Participants \>=18 years of age with suspected or confirmed malignancies planning diagnostic or therapeutic intervention from which biologic samples may be obtained.

Design:

* A tissue acquisition trial in which tissues will be obtained at the time of intervention.
* Tissue and blood will be processed at the time of collection, stored and then transferred to the Surgery Branch Cell Production Facility for further processing.
* No investigational therapy will be given.
* It is anticipated that 1200 participants will be enrolled.

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

.All IPD recorded in the medical record will be shared with intramural investigators upon request.@@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP

To collect biologic samples from participants undergoing diagnostic or therapeutic interventions for known or suspected cancer for the purpose of identifying novel molecular and biologic therapeutic targets and studying the intratumoral immune landscape.

To collect detailed history, demographic, treatment data, and perioperative findings in order to categorize specimens.

National Cancer Institute (NCI)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas	NCT04520529	Cutaneous Lymph...	Biologic Sample...	18 Years -	Assistance Publique - Hôpitaux de Paris
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment	NCT05600933	Solid Tumors Hematologic Mal... Gastrointestina... Liver Cancer Pancreatic Canc... Melanoma Pre-Malignancy Lung Cancer		18 Years -	National Institutes of Health Clinical Center (CC)
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment	NCT05600933	Solid Tumors Hematologic Mal... Gastrointestina... Liver Cancer Pancreatic Canc... Melanoma Pre-Malignancy Lung Cancer		18 Years -	National Institutes of Health Clinical Center (CC)
Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas	NCT04520529	Cutaneous Lymph...	Biologic Sample...	18 Years -	Assistance Publique - Hôpitaux de Paris
Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas	NCT04520529	Cutaneous Lymph...	Biologic Sample...	18 Years -	Assistance Publique - Hôpitaux de Paris

Spots Global Cancer Trial Database for biologic samples